Leveraging its proprietary technology platforms, Alphamab Oncology has developed a highly differentiated pipeline of novel drug candidates, including single domain antibodies, bispecific antibodies, and BADCs. Envafolimab (KN035), the world's first subcutaneously injected PD-L1 inhibitor, has received market approval, offering greater convenience and accessibility in cancer treatment. Anbenitamab (KN026), the first domestically developed HER2 bispecific antibody approved for marketing in China, redefining the standard of treatment for second‑line HER2‑positive gastric cancer. Six bispecific ADC, dual-payload ADC candidates have entered clinical stages, and next-generation ADC pipelines are advancing rapidly. Two programs were recognized by China’s “New Drug Development” initiative, four products had collectively received six FDA Orphan Drug Designations (ODD), one product was granted Breakthrough Therapy Designation (BTD) by the FDA, and three products were granted four BTDs by the NMPA.
